3-D Matrix, Ltd.

7777

JP3410730000

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 21/05/2024 BST			5-day change	1st Jan Change
131 ^JPY	-3.68%		+4.80%	-6.43%

04-04	3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.	CI
03-19	3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.	CI

3-D Matrix, Ltd. announced that it has received ¥885.0474 million in funding

November 19, 2017

On November 20, 2017, 3-D Matrix, Ltd. (JASDAQ:7777) closed the transaction.

Latest news about 3-D Matrix, Ltd.

3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.	04-03	CI
3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.	03-18	CI
3-D Matrix, Ltd.(TSE:7777) dropped from S&P Global BMI Index	18/09/23	CI
3-D Matrix, Ltd. announced that it has received ¥686.237876 million in funding from CVI Investments, Inc.	17/07/23	CI
3-D Matrix, Ltd. announced that it expects to receive ¥686.237876 million in funding from CVI Investments, Inc.	28/06/23	CI
3-D Matrix, Ltd. announced that it has received Â¥508.76 million in funding from CVI Investments, Inc.	15/03/23	CI
3-D Matrix, Ltd. announced that it expects to receive ¥508.76 million in funding from CVI Investments, Inc.	27/02/23	CI
3-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc.	16/10/22	CI
3-D Matrix, Ltd. announced that it expects to receive Ã‘2.059835568 billion in funding from CVI Investments, Inc.	29/09/22	CI
3-D Matrix, Ltd. Auditor Raises 'Going Concern' Doubt	27/07/22	CI
3-D Matrix, Ltd. announced that it has received ¥1.77192847 billion in funding from CVI Investments, Inc.	26/04/22	CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.77192847 billion in funding from CVI Investments, Inc.	10/04/22	CI
3-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc.	26/08/21	CI
3-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc.	10/08/21	CI
3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.	02/08/21	CI
3-D Matrix, Ltd. Announces Board Appointments	02/08/21	CI
3-D Matrix, Ltd. announced that it has received ¥216.0702 million in funding from CVI Investments, Inc.	25/11/20	CI
3-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc.	09/11/20	CI
3-D Matrix, Ltd. announced that it has received ¥12.8 million in funding from CVI Investments, Inc.	09/01/20	CI
3-D Matrix, Ltd. announced that it expects to receive ¥12.8 million in funding from CVI Investments, Inc.	19/12/19	CI
3-D Matrix, Ltd. announced that it has received ¥1.31202 billion in funding from CVI Investments, Inc.	14/04/19	CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.31202 billion in funding from CVI Investments, Inc.	28/03/19	CI
3-D Matrix, Ltd. announced that it has received ¥17.055 million in funding from SMBC Nikko Securities Inc., Investment Arm	16/07/18	CI
3-D Matrix, Ltd. announced that it expects to receive ¥17.055 million in funding from SMBC Nikko Securities Inc., Investment Arm	27/06/18	CI
3-D Matrix, Ltd. announced that it has received ¥885.0474 million in funding	19/11/17	CI

3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.

Sector

Biotechnology & Medical Research

Calendar

10/06/2024 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
3-D MATRIX, LTD.	-6.43%	71.15M
MODERNA, INC.	+39.78%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-1.11%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.78%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-22.09%	19B
BIO-TECHNE CORPORATION	+7.75%	13B
MEDPACE HOLDINGS, INC.	+28.09%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.10%	12.19B

Other Biotechnology & Medical Research

3-D Matrix, Ltd.

Equities

7777

JP3410730000

Biotechnology & Medical Research

3-D Matrix, Ltd. announced that it has received ¥885.0474 million in funding

Latest news about 3-D Matrix, Ltd.

Chart 3-D Matrix, Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research